Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports
Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates...
Continue Reading →
